Research from University of Cincinnati, Genome Research Institute yields new findings on obesity and diabetes therapy

New research, "mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer," is the subject of a report. "Recent studies demonstrate that the mammalian target of rapamycin (mTOR) and its effector, S6 kinase 1 (S6K1), lie at the crossroads of a nutrient-hormonal signaling network that is involved in specific pathological responses, including obesity, diabetes and cancer. mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt)," researchers in the United States...

Want to see the full article?

• Purchase this article for only $3.00